SRR10900586
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.400
- DNA_REPAIR+0.300
- FATTY_ACID_METABOLISM+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- MITOTIC_SPINDLE+0.300
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- ANGIOGENESIS-0.300
- HYPOXIA-0.300
- COAGULATION-0.200
- UV_RESPONSE_DN-0.200
- BILE_ACID_METABOLISM-0.100
- GLYCOLYSIS-0.100
- APOPTOSIS+0.000
- HEME_METABOLISM+0.000
- IL2_STAT5_SIGNALING+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2794-01A-01R-1201-07 | — | cohortSQ2 | 0.817 |
| 2 | TCGA-39-5016-01A-01R-1443-07 | — | cohortSQ2 | 0.800 |
| 3 | d5610bbc-93c5-4ca5-b687-f955d1b84c92 | — | — | 0.794 |
| 4 | SRR35579801 | — | E | 0.790 |
| 5 | SRR12696789 | — | — | 0.789 |
| 6 | SRR6013511 | — | cohortSQ1 | 0.780 |
| 7 | TCGA-33-4583-01A-01R-1443-07 | — | cohortSQ2 | 0.775 |
| 8 | TCGA-73-4666-01A-01R-1206-07 | — | cohortA1 | 0.774 |
| 9 | DRR168560 | — | — | 0.771 |
| 10 | SRR35579824 | — | E | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |